BCM
RYTM icon

BlueCrest Capital Management’s Rhythm Pharmaceuticals RYTM Stock Holding History

BlueCrest Capital Management’s Portfolio RYTM Stock Details RYTM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-9,237
Closed -$269K – 1344
2018
Q3 		$269K Buy
+9,237
New +$292K 0.01% 1097

Other funds holding RYTM

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
TG
TRV GP Boston, Massachusetts $18.9M AUM 541.67% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

BlueCrest Capital Management's RYTM Position: Q4 2018 in Review

BlueCrest Capital Management sold out of Rhythm Pharmaceuticals (RYTM) in Q4 2018, closing a stake of 9,237 shares — an estimated $269K sold.

BlueCrest Capital Management first reported a position in RYTM in Q3 2018 and held it in 1 quarter. The position peaked at $269K in Q3 2018. 74 funds tracked by Wall St. Rank hold RYTM as of Q4 2018.

  • BlueCrest Capital Management reported no remaining Rhythm Pharmaceuticals position as of Q4 2018 after selling out during the quarter.
  • BlueCrest Capital Management sold 9,237 Rhythm Pharmaceuticals shares in Q4 2018, an estimated $269K.
  • BlueCrest Capital Management first reported a position in Rhythm Pharmaceuticals in Q3 2018 and held it in 1 quarter.
  • BlueCrest Capital Management's Rhythm Pharmaceuticals position peaked at $269K in Q3 2018.
  • 74 funds tracked by Wall St. Rank held Rhythm Pharmaceuticals as of Q4 2018.

Based on BlueCrest Capital Management's 13F filing for Q4 2018, filed 14 Feb 2019.